Vesalius Biocapital, a Luxembourg-based specialist life sciences venture capital firm, held the first close of its third fund, at over €65m.
Until the final closing in 2018, Vesalius Biocapital III will accept new investors on a “rolling closing” basis. Starting immediately, the fund plans to invest in later-stage European life sciences companies across drug development, medtech, diagnostics and digital health, providing capital to support their development, with the goal of investing in 10-15 companies over the lifetime of the fund.
Led by Managing Partners Guy Geldhof, Marc Lohrmann, Dr Christian Schneider and Stéphane Verdood, Vesalius Biocapital has raised over €150m and has completed over 20 investments with lead or co-lead positions, and achieved several exits through trade sales and IPO. Recent and notable exits include Ogeda (acquired by Astellas for €800m), Activaero (sold to Vectura for €130m), Genkyotex (reverse merger on Euronext) and Fovea (acquired by Sanofi for €370m).
Venture Partners are Dr Cees Wortel and Dr David Braga Malta.